Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

What happened

Eli Lilly and Hims & Hers announced an agreement allowing eligible patients prescribed Zepbound or Foundayo through the Hims & Hers platform to access the same self-pay prices available to other patients. The platform offers consultations, prescriptions when providers consider them appropriate, and home delivery; monthly prices start at $149 for Foundayo and $299 for Zepbound.

Confirmed

Global impact / market context

The agreement links Lilly’s obesity medicines with Hims & Hers’ patient platform, creating a route from online consultations to prescriptions and medicine purchases. More completed purchases could raise Lilly’s sales, while consultations and delivery may draw patients to Hims & Hers’ services; neither company’s expected sales impact is stated.

Analyst inference

Patients pay the stated self-pay prices, rather than receiving a newly announced discount or insurance arrangement. The commercial effect depends on how many eligible patients receive prescriptions and complete purchases through the platform, which would translate the access arrangement into medicine revenue for Lilly and service activity for Hims & Hers.

Analyst inference

What to watch

1. Watch for disclosed patient uptake or sales figures: more prescriptions completed as purchases through the platform would provide evidence that the agreement is generating additional medicine revenue. Analyst inference
2. Watch for any announced changes to the arrangement, including its duration, geographic reach, or terms, since the supplied announcement does not specify these details. Analyst inference
3. Watch whether the stated monthly self-pay starting prices change: Foundayo starts at $149 and Zepbound at $299, with prescriptions dependent on provider judgment. Confirmed

Evidence

• Original source link unavailable